Biotech

Repligen (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2018. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2018 and access information for today’s webcast and conference call. As quoted in …

Repligen (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2018. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2018 and access information for today’s webcast and conference call.

As quoted in the press release:

Tony J. Hunt, President and Chief Executive Officer said, “We had a strong start to the year led by sales of our direct filtration and chromatography products, which were up by over 90% year-on-year. This includes our Spectrum business, which continues to outperform our expectations. We are also excited about the depth of our R&D pipeline which is generating new products, including our recently launched OPUS 80R pre-packed columns that address late stage clinical and commercial opportunities. Our end markets remain strong and with robust demand for our single-use and flexible bioprocessing technologies, we are raising our revenue guidance for 2018.”

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.380.00
NASD11028.740.00
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1796.89-9.97
Silver19.68-0.58
Copper3.59-0.12
Palladium1936.50+14.50
Platinum875.00-22.00
Oil107.97+2.21
Heating Oil4.00+0.17
Natural Gas5.82+0.40

DOWNLOAD FREE REPORTS

×